APAC Hospital Priorities – China Pharma Perspective

Stephen Sunderland

title slide

table of contents

hospital survey respondent mix

private vs public hospital mix

budget outlook for public hospitals

restrictions on sales rep access

hospital spending priorities

innovative drug access

barriers to NRDL drugs

spending through VBP

changes in prescription behavior

cutting back on commercial investment

change in prescription from hospitals

focus areas

value of digital health solutions

top concerns for digital health adoption

adoption of digital tools

disclaimer

thank you

Related Insights

Video / Webinar

Healthcare Services

Global Collaboration Opportunities in China's Healthcare Innovation

August 7, 2024

Published Articles

Sustainability

To Meet Decarbonization Targets, Master The Circular Economy

July 9, 2024

Executive Insights

Life Sciences & Pharma

First vs. Best in Class — Simplifying the Equation for Biopharma

June 27, 2024

Life Sciences & Pharma

Value Story and Cross-Stakeholder Action Plan for Oncology Reimbursement

May 8, 2024

A big pharma company wanted to enable change in payer attitudes to increase the acceptance of patient-reported outcomes (PROs) and of endpoints beyond…

Business Services

L.E.K. Look Forward 2024: The European Perspective

January 18, 2024

Life Sciences & Pharma

The SEA Healthcare, Medtech, and Pharma Landscape in 2023

December 7, 2023